載入...
Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
BACKGROUND: In an interim analysis of a Phase II trial in Japanese patients with pancreatic neuroendocrine tumors (panNETs), sunitinib demonstrated antitumor activity with an objective response rate (ORR) of 50% (95% confidence interval [CI], 21–79) and a median progression-free survival (PFS) of 16...
Na minha lista:
| 發表在: | Jpn J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452620/ https://ncbi.nlm.nih.gov/pubmed/30834940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyz009 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|